1. Alvarado J, Murphy C, Juster R. Trabecular meshwork cellularity in primary open-angle glaucoma and nonglaucomatous normals.
Ophthalmology 1984;91:564-579.
2. Rohen JW, Lutjen-Drecoll E, Flugel C, et al. Ultrastructure of the trabecular meshwork in untreated cases of primary open-angle glaucoma (POAG).
Exp Eye Res 1993;56:683-692.
3. Schmidl D, Schmetterer L, Garhofer G, Popa-Cherecheanu A. Pharmacotherapy of glaucoma.
J Ocul Pharmacol Ther 2015;31:63-77.
4. Kopczynski CC, Epstein DL. Emerging trabecular outflow drugs.
J Ocul Pharmacol Ther 2014;30:85-87.
5. Inoue T, Tanihara H. Rho-associated kinase inhibitors: a novel glaucoma therapy.
Prog Retin Eye Res 2013;37:1-12.
6. Thieme H, Nuskovski M, Nass JU, et al. Mediation of calcium-independent contraction in trabecular meshwork through protein kinase C and rho-A.
Invest Ophthalmol Vis Sci 2000;41:4240-4246.
7. Rao PV, Deng PF, Kumar J, Epstein DL. Modulation of aqueous humor outflow facility by the Rho kinase-specific inhibitor Y-27632.
Invest Ophthalmol Vis Sci 2001;42:1029-1037.
8. Honjo M, Tanihara H, Inatani M, et al. Effects of rho-associated protein kinase inhibitor Y-27632 on intraocular pressure and outf low facility.
Invest Ophthalmol Vis Sci 2001;42:137-144.
9. Novack GD. Rho kinase inhibitors for the treatment of glaucoma.
Drugs Future 2013;38:107-113.
10. Zhong Y, Yang Z, Huang WC, Luo X. Adenosine, adenosine receptors and glaucoma: an updated overview.
Biochim Biophys Acta 2013;1830:2882-2890.
11. Song J, Deng PF, Stinnett SS, et al. Effects of cholesterol-lowering statins on the aqueous humor outflow pathway.
Invest Ophthalmol Vis Sci 2005;46:2424-2432.
12. Stein JD, Newman-Casey PA, Talwar N, et al. The relationship between statin use and open-angle glaucoma.
Ophthalmology 2012;119:2074-2081.
13. Wiederholt M, Dorschner N, Groth J. Effect of diuretics, channel modulators and signal interceptors on contractility of the trabecular meshwork.
Ophthalmologica 1997;211:153-160.
14. Wiederholt M, Stumpff F. The trabecular meshwork and aqueous humor reabsorption. In: Civan MM, Current topics in membranes. The eye's aqueous humor: from secretion to glaucoma. Vol. 45. San Diego: Academic Press; 1998. p. 163-202.
15. Wiederholt M, Sturm A, Lepple-Wienhues A. Relaxation of trabecular meshwork and ciliary muscle by release of nitric oxide.
Invest Ophthalmol Vis Sci 1994;35:2515-2520.
16. Behar-Cohen FF, Goureau O, D'Hermies F, Courtois Y. Decreased intraocular pressure induced by nitric oxide donors is correlated to nitrite production in the rabbit eye.
Invest Ophthalmol Vis Sci 1996;37:1711-1715.
17. Dismuke WM, Mbadugha CC, Ellis DZ. NO-induced regulation of human trabecular meshwork cell volume and aqueous humor outf low facility involve the BKCa ion channel.
Am J Physiol Cell Physiol 2008;294:C1378-C1386.
18. Rikitake Y, Liao JK. Rho GTPases, statins, and nitric oxide.
Circ Res 2005;97:1232-1235.
19. Noma K, Oyama N, Liao JK. Physiological role of ROCKs in the cardiovascular system.
Am J Physiol Cell Physiol 2006;290:C661-C668.
20. Bradley JM, Vranka J, Colvis CM, et al. Effect of matrix metalloproteinases activity on outflow in perfused human organ culture.
Invest Ophthalmol Vis Sci 1998;39:2649-2658.
21. Sanka K, Maddala R, Epstein DL, Rao PV. Influence of actin cytoskeletal integrity on matrix metalloproteinase-2 activation in cultured human trabecular meshwork cells.
Invest Ophthalmol Vis Sci 2007;48:2105-2114.
22. Shearer TW, Crosson CE. Adenosine A1 receptor modulation of MMP-2 secretion by trabecular meshwork cells.
Invest Ophthalmol Vis Sci 2002;43:3016-3020.
23. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays.
J Immunol Methods 1983;65:55-63.
24. Kameda T, Inoue T, Inatani M, et al. The effect of Rho-associated protein kinase inhibitor on monkey Schlemm's canal endothelial cells.
Invest Ophthalmol Vis Sci 2012;53:3092-3103.
25. Alvarado JA, Betanzos A, Franse-Carman L, et al. Endothelia of Schlemm's canal and trabecular meshwork: distinct molecular, functional, and anatomic features.
Am J Physiol Cell Physiol 2004;286:C621-C634.
26. Green LC, Wagner DA, Glogowski J, et al. Analysis of nitrate, nitrite, and [15N]nitrate in biological fluids.
Anal Biochem 1982;126:131-138.
27. Alvarado JA, Wood I, Polansky JR. Human trabecular cells. II. Growth pattern and ultrastructural characteristics.
Invest Ophthalmol Vis Sci 1982;23:464-478.
28. Zhang M, Maddala R, Rao PV. Novel molecular insights into RhoA GTPase-induced resistance to aqueous humor outflow through the trabecular meshwork.
Am J Physiol Cell Physiol 2008;295:C1057-C1070.
29. Husain S, Shearer TW, Crosson CE. Mechanisms linking adenosine A1 receptors and extracellular signal-regulated kinase 1/2 activation in human trabecular meshwork cells.
J Pharmacol Exp Ther 2007;320:258-265.
30. Fleischhauer JC, Mitchell CH, Stamer WD, et al. Common actions of adenosine receptor agonists in modulating human trabecular meshwork cell transport.
J Membr Biol 2003;193:121-136.
31. Kim HY, Kim JW. Effect of nitric oxide on the permeability of trabecular meshwork cell monolayer.
J Korean Ophthalmol Soc 2015;56:771-775.
32. Satoh K, Fukumoto Y, Shimokawa H. Rho-kinase: important new therapeutic target in cardiovascular diseases.
Am J Physiol Heart Circ Physiol 2011;301:H287-H296.
33. Honjo M, Tanihara H, Kameda T, et al. Potential role of Rho-associated protein kinase inhibitor Y-27632 in glaucoma filtration surgery.
Invest Ophthalmol Vis Sci 2007;48:5549-5557.
34. Tanihara H, Inoue T, Yamamoto T, et al. Intra-ocular pressure-lowering effects of a Rho kinase inhibitor, ripasudil (K-115), over 24 hours in primary open-angle glaucoma and ocular hypertension: a randomized, open-label, crossover study.
Acta Ophthalmol 2015;93:e254-e260.
35. Kaneko Y, Ohta M, Inoue T, et al. Effects of K-115 (Ripasudil), a novel ROCK inhibitor, on trabecular meshwork and Schlemm's canal endothelial cells.
Sci Rep 2016;6:19640
36. Ichikawa M, Yoshida J, Saito K, et al. Differential effects of two ROCK inhibitors, Fasudil and Y-27632, on optic nerve regeneration in adult cats.
Brain Res 2008;1201:23-33.
37. Hata Y, Miura M, Nakao S, et al. Antiangiogenic properties of fasudil, a potent Rho-kinase inhibitor.
Jpn J Ophthalmol 2008;52:16-23.
38. Novack GD. Eyes on new product development.
J Ocul Pharmacol Ther 2016;32:401-402.
39. Prasanna G, Li B, Mogi M, Rice DS. Pharmacology of novel intraocular pressure-lowering targets that enhance conventional outflow facility: pitfalls, promises and what lies ahead?
Eur J Pharmacol 2016;787:47-56.